Literature DB >> 103551

Comparative disposition of sulindac and metabolites in five species.

D E Duggan, K F Hooke, R M Noll, H B Hucker, C G Van Arman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 103551     DOI： 10.1016/0006-2952(78)90137-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  13 in total

Review 1.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 3.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.

Authors:  Jin Kyung Lee; Mary F Paine; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

5.  Validation of a column-switching high-performance liquid chromatographic (HPLC) method for determination of ML-1035 and its five metabolites in plasma.

Authors:  B S Kuo; J C Poole; K K Hwang
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

Review 6.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 7.  The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly.

Authors:  K W Woodhouse; H Wynne
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

8.  A liner mode of reversible metabolism and its application to bioavailability assessment.

Authors:  S Hwang; K C Kwan; K S Albert
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

9.  A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Yong Zhang; Jinhui Zhang; Lei Wang; Emily Quealy; Bernard D Gary; Robert C Reynolds; Gary A Piazza; Junxuan Lü
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

10.  A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

Authors:  Gary A Piazza; Adam B Keeton; Heather N Tinsley; Bernard D Gary; Jason D Whitt; Bini Mathew; Jose Thaiparambil; Lori Coward; Gregory Gorman; Yonghe Li; Brahma Sani; Judith V Hobrath; Yulia Y Maxuitenko; Robert C Reynolds
Journal:  Cancer Prev Res (Phila)       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.